Preferred outsourcing in clinical development among biopharma companies by size 2023
According to a survey conducted in 2023, nearly 40 percent of surveyed biopharma executives stated that the full-service model is the preferred outsourcing model for their clinical development work. This statistic describes the distribution of preferred outsourcing models in clinical development among biopharmaceutical companies worldwide, by the size of the company.